NordShield® Brilliant series is now dermatologically tested with the rating of „excellent“

Espoo, 11 November 2021 – Nordic BioTech Group Ltd, marketed as NordShield® ("NordShield®") has completed new dermatological tests for its cutting edge disinfectants of the NordShield® Brilliant series.


The entire NordShield® Brilliant series has received the 3-star quality seal and rating “excellent” in dermatological tests conducted by renown Dermatest GmbH in Germany.


NordShield® Brilliant ready products, marketed as NordShield® Brilliant Hands,

NordShield® Brilliant Surfaces, and NordShield® Brilliant Fresh (latter used against bad odor in shoes, feet and performance gear) have been “dermatologically tested”. The tests have been done for sensitisation according to a repetitive epicutaneous test (occlusive patch test) for primary skin irritation and detection of sensitisation of humans based on three applications within seven weeks of NordShield® Brilliant and been given a rating of „excellent“. This testing on humans was performed by Dermatest® GmbH (ISO 9001:2015) on 30 panellists of either sex, all without visible skin diseases or known hypersensitivity.


Under the conditions of this study NordShield® Brilliant ready products fulfil the following statements:

  • No evidence of any skin disorder was detected in the test area of any of the 30 panellists after conducting patch testing for 24 h, 48 h and 72 hours according to the internationally recognised guidelines of ICDRG (International Contact Dermatitis Research Group).

  • During the first two patch tests in week 1 and 3, the test persons were intensively contacted with the test substance. With the third epicutaneous test in week 7, a possible very high sensitization potential of the preparation was largely excluded.”

  • None of the 30 test persons presented any allergic or allergic-hyperergic reactions in the third and therefore conclusive patch test.

  • It can be concluded that the use of the product will not cause any unwanted skin reactions due to an irritating effect.

  • Contract trademark (Dermatest® 3-star quality seal) can be used by Nordic BioTech Group Ltd in reference to NordShield® Brilliant products


____


About NordShield®

Nordic BioTech Group, branded as NordShield®, is the world-leading innovative biotechnology company in the field of developing new bio-based antimicrobial solutions. Founded in 2016 and headquartered in Espoo, Finland, NordShield® is disrupting the field of antimicrobial technology through a durable, wood-based alternative for antimicrobial surface protection utilized across applications and industries. NordShield® as a commercial technology was born after more than ten years of researching, developing, testing, verifying, certifying, and patenting. The result is a revolutionary technology with a unique combination of naturality, power and efficacy. This scalable technology enables the strongest protection with the highest innovativeness - a creation as unique and powerful as nature and one that leaves nothing but goodness behind.


For more information, visit www.nordshield.com


Contact to NordShield®:

Emmi Kavander, Chief Communications Officer / NordShield®

emmi.kavander(a)nordshield.cominfo@nordshield.com



Disclaimer:

This document may contain statements related to Nordic Biotech Group Ltd's future business and financial performance and future events or developments that may constitute forward-looking statements. Nordic BioTech Group Oy does not make any representation or warranty, express or implied, as to the accuracy, completeness, or updated status of any such statements. Nordic Biotech Group neither intends nor assumes any obligation to update or revise these statements in light of developments that differ from those anticipated. Nordic BioTech Group Oy and its affiliates are not liable for any decision made or action taken in conjunction with the information and/or statement in this document or for any related damage.


This document contains statements that are only applicable within the European Union, and this document is intended only for distribution within the European Union. Nordic BioTech Group Oy does not make any representation or warranty, express or implied, as to the accuracy, completeness or updated status of any such statements and is not liable for any such statements.